百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BGNE 百济神州

交易中 05-03 15:59:59 EDT

161.96

-0.05

-0.03%

最高162.51	最低159.32	成交量18.82万
今开162.51	昨收162.01	日振幅1.97%
总市值169.28亿	流通市值94.95亿	总股本1.05亿
成交额3,036万	换手率0.32%	流通股本5,862万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BGNE","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":161.96,"timestamp":1714766399113,"preClose":162.01,"halted":0,"volume":188218,"delay":0,"floatShares":58623265,"shares":104517977,"eps":-8.446508,"marketStatus":"交易中","marketStatusCode":2,"change":-0.05,"latestTime":"05-03 15:59:59 EDT","open":162.51,"high":162.51,"low":159.32,"amount":30363679.727659997,"amplitude":0.01969,"askPrice":162.25,"askSize":19,"bidPrice":161.9,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-8.446508,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1714766400000},"adr":1,"adjPreClose":162.01,"adrRate":13,"volumeRatio":0.900762},"requestUrl":"/m/hq/s/BGNE/","defaultTab":"news","newsList":[{"id":"2432601145","title":"百济神州盘中异动 大幅拉升5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432601145","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432601145?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:34","pubTimestamp":1714656879,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日21时34分，百济神州股票出现波动，股价急速拉升5.16%。截至发稿，该股报164.60美元/股，成交量1.4866万股，换手率0.01%，振幅2.60%。百济神州股票所在的生物技术行业中，整体跌幅为0.30%。百济神州公司简介：百济神州有限公司是一家处于商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050221343987e85544&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050221343987e85544&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432662648","title":"百济神州(06160)4月30日于股份奖励计划下发行26.182万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2432662648","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432662648?lang=zh_cn&edition=full","pubTime":"2024-05-02 08:03","pubTimestamp":1714608198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)公布，2024年4月30日，于股份奖励计划下发行26.182万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116794.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432663541","title":"百济神州上涨2.03%，报157.065美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432663541","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432663541?lang=zh_cn&edition=full","pubTime":"2024-05-02 02:56","pubTimestamp":1714589807,"startTime":"0","endTime":"0","summary":"5月2日，百济神州(BGNE)盘中上涨2.03%，截至02:56，报157.065美元/股，成交945.13万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：5月2日，百济神州将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/02025640507588.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431314652","title":"百济神州PD-1抑制剂百泽安®在中国获批第13项适应症申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2431314652","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2431314652?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:47","pubTimestamp":1714474020,"startTime":"0","endTime":"0","summary":"\" 在中国，替雷利珠单抗已有13项适应症申请获得国家药监局批准。总计11项已纳入国家医保药品目录，是目前纳入国家医保药品目录获批适应症数量最多的PD-1抑制剂。百济神州已开展超过17项替雷利珠单抗的潜在注册性临床试验，其中已有11项3期随机试验和4项2期试验取得积极结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4401278_ZH01278_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431022008","title":"百济神州的“溢出效应”","url":"https://stock-news.laohu8.com/highlight/detail?id=2431022008","media":"钛媒体APP","top":-1,"share":"https://www.laohu8.com/m/news/2431022008?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:27","pubTimestamp":1714440465,"startTime":"0","endTime":"0","summary":"目前来看，百济神州无疑会成为创新药产业具有示范意义的标杆。除此之外，PD-1持续出海、潜力管线的持续打造，百济神州不断刷新市场认知的同时，也将为创新药行业带来深远的溢出效应。事实上，百济神州2023年财报的公布，已经为整个创新药行业注入了信心。百济神州基于对药物临床开发的前瞻性布局，开展了诸多全球临床试验。外界有声音认为，百济神州的成功大部分得益于“钞能力”，尤其是在人才薪酬支出层面“舍得花钱”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043009320187c18bef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043009320187c18bef&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431762871","title":"百济神州(06160)因受限制股份单位获归属而发行约23.86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431762871","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431762871?lang=zh_cn&edition=full","pubTime":"2024-04-30 07:43","pubTimestamp":1714434209,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)公布，2024年4月29日，因根据股权计划授出的受限制股份单位获归属而发行约23.86万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1115988.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431958078","title":"百济神州上涨2.04%，报156.72美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431958078","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431958078?lang=zh_cn&edition=full","pubTime":"2024-04-29 23:09","pubTimestamp":1714403389,"startTime":"0","endTime":"0","summary":"4月29日，百济神州(BGNE)盘中上涨2.04%，截至23:09，报156.72美元/股，成交807.2万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：5月2日，百济神州将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/29230940478598.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431047144","title":"南向资金4月26日净买入百济神州48.61万股 连续7日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2431047144","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431047144?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:31","pubTimestamp":1714354293,"startTime":"0","endTime":"0","summary":"4月26日, 南向资金增持百济神州48.61万股，连续7日增持。截止当日收盘，港股通共持有百济神州5392.41万股，占流通股3.96%。百济神州近5个交易日上涨19.42%，港股通累计增持159.82万股；近20个交易日下跌1.82%，港股通累计增持303.77万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042909480487bcb483&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042909480487bcb483&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431490340","title":"北向资金4月26日净买入百济神州-U6.93万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2431490340","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431490340?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:30","pubTimestamp":1714354238,"startTime":"0","endTime":"0","summary":"4月26日, 北向资金增持百济神州-U6.93万股，连续5日增持。截止当日收盘，沪股通共持有百济神州-U556.32万股，占流通股4.83%。沪股通增持金额前五个股分别为招商银行、贵州茅台、兴业银行、药明康德、三一重工。百济神州-U近5个交易日上涨12.44%，沪股通累计增持26.24万股；近20个交易日上涨0.41%，沪股通累计增持69.72万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404290937088b5f9e13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404290937088b5f9e13&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431201061","title":"百济神州(06160)因受限制股份单位获归属而发行约12.1万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2431201061","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2431201061?lang=zh_cn&edition=full","pubTime":"2024-04-29 08:13","pubTimestamp":1714349612,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)公布，2024年4月28日，因根据股权计划授出的受限制股份单位获归属而发行约12.1万股股份。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113831.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430032658","title":"百济神州2023年营收174亿：同比增82% 净亏67亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2430032658","media":"雷递网","top":-1,"share":"https://www.laohu8.com/m/news/2430032658?lang=zh_cn&edition=full","pubTime":"2024-04-28 18:05","pubTimestamp":1714298743,"startTime":"0","endTime":"0","summary":"百济神州有限公司（公司代码：688235，公司简称：百济神州）日前发布2023年财报。财报显示，百济神州2023年营收为174.23亿元，较上年同期的95.66亿元增长82.13%。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240428/6384992434012489854792567.jpg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240428/6384992434012489854792567.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.leinews.com/n26447/detail.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430039240","title":"注意！百济神州将于6月5日召开股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2430039240","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430039240?lang=zh_cn&edition=full","pubTime":"2024-04-28 16:43","pubTimestamp":1714293832,"startTime":"0","endTime":"0","summary":"百济神州（SH688235，收盘价：130.77元）4月28日发布公告称，2024年6月5日21点30分，公司将在MourantGovernanceServicesLimited的办公室，位于94SolarisAvenueCamanaBayGrandCaymanKY1-1108开曼群岛召开2024年年度股东大会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404283062723670.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404283062723670.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430846930","title":"百济神州：2023年净亏损67.16亿元，尚未盈利存在累计亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2430846930","media":"经济观察报","top":-1,"share":"https://www.laohu8.com/m/news/2430846930?lang=zh_cn&edition=full","pubTime":"2024-04-28 15:19","pubTimestamp":1714288790,"startTime":"0","endTime":"0","summary":"财报速读4月27日，百济神州（688235）发布2023年年报。2023年百济神州实现营业收入174.23亿元，同比增加82.13%；归母净利润为-67.16亿元，较上年同期-136.42亿元亏损缩窄；归母扣非净亏损为96.82亿元，公司累计未弥补亏损为人民币 576.88 亿元，存在大额累计及持续亏损。去除了股份支付费用、折旧及摊销费用等非现金项目影...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/Ofcx1XzT2lmBjmB-q1iqSm_Xyo0D75L4lubPWYkCeV8pUAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Ofcx1XzT2lmBjmB-q1iqSm_Xyo0D75L4lubPWYkCeV8pUAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240428A057UC00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240428A057UC00","is_publish_highlight":false,"gpt_icon":0},{"id":"2430706662","title":"百济神州2023年营收174.23亿 核心市场产品销售额增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2430706662","media":"挖贝网","top":-1,"share":"https://www.laohu8.com/m/news/2430706662?lang=zh_cn&edition=full","pubTime":"2024-04-28 10:46","pubTimestamp":1714272384,"startTime":"0","endTime":"0","summary":"挖贝网4月28日，百济神州 近日发布2023年年度报告，报告期内公司实现营业收入17,423,344千元，同比增长82.13%；归属于上市公司股东的净利润-6,715,859千元，较上年同期亏损减少。报告期内公司实现营业收入17,423,344千元，同比增长82.13%；主要系公司核心市场产品销售额的增长所致。公告显示，报告期内董事、监事、高级管理人员报酬合计6,033.66万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281047478b5c5c82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281047478b5c5c82&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430798726","title":"百济神州亏损缩窄50%，核心产品成国内首个“十亿美元分子”","url":"https://stock-news.laohu8.com/highlight/detail?id=2430798726","media":"蓝鲸财经","top":-1,"share":"https://www.laohu8.com/m/news/2430798726?lang=zh_cn&edition=full","pubTime":"2024-04-27 14:34","pubTimestamp":1714199648,"startTime":"0","endTime":"0","summary":"2024年4月26日，百济神州发布A股2023年年度报告。2023年，百济神州全球营业收入174.23亿元，同比增长82.1%，报告期内公司归属净利润同比减亏，对应实现的归属净利润约为-67.16亿元，同比增长50.77%。财报显示，2023年其核心产品泽布替尼作为中国创新药出海的代表，全球销售额较上年同期了138.7%，达到91.38亿元，成为国内首个年销售额超过十亿美元的国产创新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/231144","is_publish_highlight":false,"gpt_icon":0},{"id":"2430376191","title":"百济神州：2023年度净利润约-67.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430376191","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430376191?lang=zh_cn&edition=full","pubTime":"2024-04-27 11:43","pubTimestamp":1714189402,"startTime":"0","endTime":"0","summary":"百济神州（SH688235，收盘价：130.77元）4月27日发布年度业绩报告称，2023年营业收入约174.23亿元，同比增加82.13%；归属于上市公司股东的净利润亏损约67.16亿元；基本每股收益亏损4.95元。2022年同期营业收入约95.66亿元；归属于上市公司股东的净利润亏损约136.42亿元；基本每股收益亏损10.18元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404273062218596.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404273062218596.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430646727","title":"百济神州2023年实现营收174.23亿元 同比增长82.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430646727","media":"经济参考网","top":-1,"share":"https://www.laohu8.com/m/news/2430646727?lang=zh_cn&edition=full","pubTime":"2024-04-27 11:42","pubTimestamp":1714189365,"startTime":"0","endTime":"0","summary":"4月26日，百济神州（688235.SH）发布A股2023年报。公司去年实现营业收入174.23亿元，同比增长82.1%。全年产品收入再创突破，达155.04亿元，同比增长82.8%。产品收入增长强劲2023年，百济神州加速全球业务发展，以两款自主研发药物为增长引擎，商业化领先优势进一步扩大。百济神州产品收入大幅增长的驱动力，主要来自BTK抑制剂百悦泽?（泽布替尼）的全球放量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404273062230389.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430763350","title":"百济神州2023年净亏损缩窄约50% 研发投入是业内平均水平的8倍，仍然坚持“去CRO”","url":"https://stock-news.laohu8.com/highlight/detail?id=2430763350","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430763350?lang=zh_cn&edition=full","pubTime":"2024-04-27 10:55","pubTimestamp":1714186511,"startTime":"0","endTime":"0","summary":"百济神州（688235.SH，股价130.77元，市值1776.35亿元）甩开恒瑞医药（600276.SH，股价45.61元，市值2909.46亿元），继续稳坐国内创新药“一哥”交椅。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404273062194250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404273062194250.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430785433","title":"图解百济神州年报：第四季度单季净利润同比增11.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430785433","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430785433?lang=zh_cn&edition=full","pubTime":"2024-04-27 01:05","pubTimestamp":1714151133,"startTime":"0","endTime":"0","summary":"证券之星消息，百济神州2023年年报显示，公司主营收入174.23亿元，同比上升82.13%；归母净利润-67.16亿元，同比上升50.77%；扣非净利润-96.82亿元，同比上升29.97%；其中2023年第四季度，公司单季度主营收入45.48亿元，同比上升68.6%；单季度归母净利润-28.38亿元，同比上升11.55%；单季度扣非净利润-28.99亿元，同比上升11.52%；负债率38.95%，投资收益1.67亿元，财务费用1.97亿元，毛利率84.57%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042701053687b4808c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042701053687b4808c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430427294","title":"百济神州(688235.SH)发2023年度业绩，营收大涨82.13%至174.23亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430427294","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430427294?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:19","pubTimestamp":1714137588,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布2023年年度报告，报告期内公司实现营业收入174.23亿元，同比大涨82.13%;归属于上市公司股东的净亏损大幅收窄至67.16亿元。百泽安已在中国获批用于12项适应症，其中11项适应症已纳入国家医保目录，其广泛的全球临床布局包括在超过30个国家和地区入组受试者超过13,000人。公司已重获百泽安开发、生产和商业化的全球权利，加强公司在实体肿瘤领域的全球产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112378.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":0.0905},{"period":"1month","weight":0.0572},{"period":"3month","weight":0.1213},{"period":"6month","weight":-0.1185},{"period":"1year","weight":-0.3886},{"period":"ytd","weight":-0.1017}],"compareEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":-0.0266},{"period":"3month","weight":0.0216},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.0625}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BeiGene Ltd是一家全球生物技术公司，致力于为全球癌症患者发现和开发肿瘤治疗方法。该公司已发现并开发三种批准药物，包括BRUKINSA，一种布鲁顿酪氨酸激酶的小分子抑制剂，用于治疗各种血癌；TEVIMBRA（tislelizumab），一种抗PD-1抗体免疫疗法，用于治疗各种实体瘤和血癌；以及是聚ADP核糖聚合酶1(PARP1)和PARP2的选择性小分子抑制剂pamiparib。该公司已获得在美国、中华人民共和国（中国）、欧盟、英国、加拿大、澳大利亚和其他国际市场销售BRUKINSA，在欧盟和中国销售替雷利珠单抗，以及在中国销售帕米帕尼的批准。它还专注于在Amgen Inc独家授权下在中国商业化癌症药物，如XGEVA、BLINCYTO、KYPROLIS等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.062331},{"month":2,"riseRate":0.625,"avgChangeRate":0.017001},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.028933},{"month":4,"riseRate":0.444444,"avgChangeRate":0.028699},{"month":5,"riseRate":0.555556,"avgChangeRate":-0.005631},{"month":6,"riseRate":0.625,"avgChangeRate":0.022561},{"month":7,"riseRate":0.75,"avgChangeRate":0.132564},{"month":8,"riseRate":0.5,"avgChangeRate":0.021799},{"month":9,"riseRate":0.5,"avgChangeRate":0.051436},{"month":10,"riseRate":0.625,"avgChangeRate":0.017618},{"month":11,"riseRate":0.5,"avgChangeRate":0.059889},{"month":12,"riseRate":0.375,"avgChangeRate":-0.023463}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BeiGene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,BGNE,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}